Unleashing the potential of CD39-targeted cancer therapy: Breaking new ground and future prospects

Qiongyan Zhou; Shengwen Shao; Theia Minev; Wenxue Ma

Biomedicine & Pharmacotherapy (Sep 2024)

Unleashing the potential of CD39-targeted cancer therapy: Breaking new ground and future prospects

Qiongyan Zhou,
Shengwen Shao,
Theia Minev,
Wenxue Ma

Affiliations

Qiongyan Zhou: Department of Dermatology, The First Affiliated Hospital of Ningbo University School of Medicine, Ningbo, Zhejiang 315020, China
Shengwen Shao: Institute of Microbiology and Immunology, Huzhou University School of Medicine, Huzhou, Zhejiang 313000, China
Theia Minev: Cure Science Institute, San Diego, CA 92121, USA
Wenxue Ma: Corresponding author.; Department of Medicine, Sanford Stem Cell Institute and Moores Cancer Center, University of California San Diego, La Jolla, CA 92093, USA

Journal volume & issue: Vol. 178
p. 117285

Abstract

Read online

The review article titled CD39 Transforming Cancer Therapy by Modulating Tumor Microenvironment published in June 2024 in Cancer Letters provides a comprehensive overview of CD39's multifaceted roles in cancer, particularly its influence on immunoregulation, angiogenesis, and metabolic reprogramming within the tumor microenvironment (TME). This commentary builds on that foundation by incorporating recent advancements in CD39 research, highlighting unresolved issues, and proposing future research directions. We delve into the therapeutic potential of targeting CD39, addressing clinical translation challenges, and exploring the integration of CD39-based strategies into precision oncology.

Published in Biomedicine & Pharmacotherapy

ISSN: 0753-3322 (Print); 1950-6007 (Online)
Publisher: Elsevier
Country of publisher: France
LCC subjects: Medicine: Therapeutics. Pharmacology
Website: https://www.journals.elsevier.com/biomedicine-and-pharmacotherapy

About the journal

Abstract

Keywords